DMBT1: A Drug Target / Disease Biomarker (G1755)

Target Name: DMBT1

NCBI ID: G1755

DMBT1

DMBT1: A Drug Target / Disease Biomarker

DMBT1, short for dopamine-beta-transporter subunit, is a protein that is expressed in the brain and plays a crucial role in the transportation of dopamine, a neurotransmitter that is responsible for mood, emotion, and motivation. There is a growing interest in DMBT1 as a drug target due to its potential to treat various psychiatric and neurological disorders.

DMBT1 is a transmembrane protein that is expressed in the brain and is composed of two main subunits, alpha and beta. The alpha subunit is predominantly expressed in the prefrontal cortex, while the beta subunit is predominantly expressed in the basal ganglia. DMBT1 functions as a receptor for dopamine, which binds to the protein and transports it to the dopamine transporter, a protein that transports dopamine-containing vesicles to theendostrils of the synapse.

Studies have shown that DMBT1 is involved in the regulation of various physiological processes in the brain, including mood, emotion, and motivation. For example, DMBT1 has been shown to play a role in regulating the release of neurotransmitters, such as dopamine, in response to environmental stimuli. It has also been shown to modulate the activity of other neurotransmitters, such as GABA, a inhibitory neurotransmitter.

In addition to its role in neurotransmitter regulation, DMBT1 has also been shown to play a role in the development and progression of various psychiatric and neurological disorders. For example, DMBT1 has been shown to be reduced in individuals with major depressive disorder and in individuals with schizophrenia, a disorder characterized by the absence of clear symptoms of depression or mania.

Because of its potential as a drug target, DMBT1 has become a focus of research in the pharmaceutical industry. Currently, there are several drug candidates that are being developed to target DMBT1, including both small molecules and antibodies. These drugs are being tested for their potential to treat various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia.

One of the most promising drug candidates is a small molecule called RG-1212, which is currently being tested for the treatment of depression. RG-1212 is a selective inhibitor of DMBT1, which means that it only targets the alpha subunit of DMBT1 and does not affect the beta subunit. Preclinical studies have shown that RG-1212 is effective in reducing the symptoms of depression, including low mood and anhedonia, and that it has a beneficial effect on the structure and function of the brain.

Another drug candidate is a monoclonal antibody called AMG 701, which is being developed by Neurocrine Biosciences. AMG 701 is designed to target the alpha subunit of DMBT1 and is being tested for the treatment of depression. Preclinical studies have shown that AMG 701 is effective in reducing the symptoms of depression and that it has a beneficial effect on the structure and function of the brain.

While DMBT1 is a promising drug target, there are also potential drawbacks to its use. For example, DMBT1 has been shown to be expressed in various tissues and organs, including the brain, heart, and liver. This means that it could be potential for DMBT1 to cause unintended side effects in these tissues. In addition, DMBT1 has been shown to be involved in the regulation of various physiological processes in the brain, including mood and emotion. This means that it could have unintended effects on these processes and potentially cause harm.

Despite these potential drawbacks, the potential benefits of DMBT1 as a drug target are too great to ignore. If successful, DMBT1-targeted drugs have the potential to treat a wide range of psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. These drugs could also have

Protein Name: Deleted In Malignant Brain Tumors 1

Functions: May be considered as a candidate tumor suppressor gene for brain, lung, esophageal, gastric, and colorectal cancers. May play roles in mucosal defense system, cellular immune defense and epithelial differentiation. May play a role as an opsonin receptor for SFTPD and SPAR in macrophage tissues throughout the body, including epithelial cells lining the gastrointestinal tract. May play a role in liver regeneration. May be an important factor in fate decision and differentiation of transit-amplifying ductular (oval) cells within the hepatic lineage. Required for terminal differentiation of columnar epithelial cells during early embryogenesis. May function as a binding protein in saliva for the regulation of taste sensation. Binds to HIV-1 envelope protein and has been shown to both inhibit and facilitate viral transmission. Displays a broad calcium-dependent binding spectrum against both Gram-positive and Gram-negative bacteria, suggesting a role in defense against bacterial pathogens. Binds to a range of poly-sulfated and poly-phosphorylated ligands which may explain its broad bacterial-binding specificity. Inhibits cytoinvasion of S.enterica. Associates with the actin cytoskeleton and is involved in its remodeling during regulated exocytosis. Interacts with pancreatic zymogens in a pH-dependent manner and may act as a Golgi cargo receptor in the regulated secretory pathway of the pancreatic acinar cell

The "DMBT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMBT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets